Advertisement

Topics

MSD plays catch up with €464m deal for fledgling biotech

04:16 EDT 7 Sep 2017 | Pharmafile

MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 million and with further payments worth up to €349 million. The biotech only recently completed a recent Series A financing round that brought in close to €30 million, making MSD’s buyout a huge success for investors and a show of faith from MSD in the technology behind the company.

read more

Original Article: MSD plays catch up with €464m deal for fledgling biotech

NEXT ARTICLE

More From BioPortfolio on "MSD plays catch up with €464m deal for fledgling biotech"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...